Relapsed or refractory Classical Hodgkins Lymphoma and relapsed or refractory Primary Mediastinal Large B-cell Lymphoma research hub

A Phase 2 Study of Pembrolizumab (MK-3475) every 6 weeks (Q6W) in Participants with Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)

This study is testing a new medicine called Keytruda for people in the UK with certain types of lymphoma that have come back or not responded to previous treatments. It aims to see how well Keytruda shrinks the lymphoma and if it is safe.